dc.contributorMartinez-Albarran, M., Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Departamento de Hematología Y Oncología Pediátrica, Salvador Quevedo y Zubieta 750. Colonia Independencia, Guadalajara, Jalisco, CP 44340, Mexico; Perez-Molina, J.D.J., Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Departamento de Hematología Y Oncología Pediátrica, Salvador Quevedo y Zubieta 750. Colonia Independencia, Guadalajara, Jalisco, CP 44340, Mexico; Gallegos-Castorena, S., Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Departamento de Hematología Y Oncología Pediátrica, Salvador Quevedo y Zubieta 750. Colonia Independencia, Guadalajara, Jalisco, CP 44340, Mexico; Sanchez-Zubieta, F., Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Departamento de Hematología Y Oncología Pediátrica, Salvador Quevedo y Zubieta 750. Colonia Independencia, Guadalajara, Jalisco, CP 44340, Mexico; Del Toro-Arreola, S., Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Departamento de Fisiología, Guadalajara, Jalisco, Mexico; Troyo-Sanroman, R., Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Departamento de Fisiología, Guadalajara, Jalisco, Mexico; Gonzalez-Ramella, O., Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Departamento de Hematología Y Oncología Pediátrica, Salvador Quevedo y Zubieta 750. Colonia Independencia, Guadalajara, Jalisco, CP 44340, Mexico
dc.creatorMartinez-Albarran, M.
dc.creatorPerez-Molina, J.D.J.
dc.creatorGallegos-Castorena, S.
dc.creatorSanchez-Zubieta, F.
dc.creatorDel Toro-Arreola, S.
dc.creatorTroyo-Sanroman, R.
dc.creatorGonzalez-Ramella, O.
dc.date.accessioned2015-11-19T18:52:02Z
dc.date.accessioned2023-07-03T22:28:16Z
dc.date.available2015-11-19T18:52:02Z
dc.date.available2023-07-03T22:28:16Z
dc.date.created2015-11-19T18:52:02Z
dc.date.issued2009
dc.identifierhttp://hdl.handle.net/20.500.12104/67265
dc.identifier10.1080/08880010903044797
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-68649107118&partnerID=40&md5=735e3328bcc406fc5a8b3639fe7140fd
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7245513
dc.description.abstractBackground: Procalcitonin and C-reactive-protein are inflammatory markers for sepsis. The authors evaluated their sensitivity and specificity in pediatric patients with cancer and febrile neutropenia. Procedure: Serum procalcitonin and C-reactive-protein were evaluated. Patients (n = 54) were divided into 2 groups, with severe infection (n = 18) or without documented infection (n = 36). Results: Procalcitonin and C-reactive protein were significantly higher in the high-risk group. Procalcitonin displayed 72.2% sensitivity and 80.5% specificity. C-reactive-protein had a sensitivity of 77.7% and specificity of 77.2%. Conclusions: Procalcitonin is an accurate predictor of bacterial infection in neutropenic children, while C-reactive-protein may be a better screening test in emergency settings. Copyright © Informa Healthcare USA, Inc.
dc.relationPediatric Hematology and Oncology
dc.relation26
dc.relation6
dc.relation414
dc.relation425
dc.relationScopus
dc.relationWOS
dc.titleProcalcitonin and C-reactive protein serum levels as markers of infection in a pediatric population with febrile neutropenia and cancer
dc.typeArticle


Este ítem pertenece a la siguiente institución